[Form 4] METLIFE INC Insider Trading Activity
Denise M. Morrison, identified as a director of MetLife, Inc. (MET), reported a non-derivative acquisition of 534 shares of MetLife common stock on 10/01/2025. The shares were issued as part of MetLife's non-management director compensation and recorded with a price of $0 (retainer paid in stock). Following the transaction the reporting person beneficially owned 33,351 shares. The Form 4 filing was signed on 10/03/2025 by an attorney-in-fact. The disclosure states these shares represent a portion of the director retainer paid in company stock.
Denise M. Morrison, identificata come direttrice di MetLife, Inc. (MET), ha riportato un'acquisizione non derivativa di 534 azioni ordinarie MetLife in data 10/01/2025. Le azioni sono state emesse come parte della retribuzione dei membri non esecutivi del consiglio e registrate con un prezzo di $0 (il retainer è stato pagato in azioni). In seguito alla transazione la persona che riporta possedeva in modo utile 33.351 azioni. Il filing Form 4 è stato firmato il 10/03/2025 da un procuratore. La disclosure afferma che queste azioni rappresentano una parte del retainer del direttore pagato in azioni della società.
Denise M. Morrison, identificada como directora de MetLife, Inc. (MET), reportó una adquisición no derivativa de 534 acciones comunes de MetLife el 10/01/2025. Las acciones fueron emitidas como parte de la compensación para directores no ejecutivos y registradas a un precio de $0 (retención pagada en acciones). Tras la transacción, la persona reportante posee beneficiosamente 33.351 acciones. La presentación del Formulario 4 fue firmada el 10/03/2025 por un agente autorizado. La divulgación indica que estas acciones representan una parte de la retención del director pagada en acciones de la empresa.
Denise M. Morrison은 MetLife, Inc. (MET)의 이사로 식별되며, 2025년 10월 1일에 MetLife 보통주 534주의 비파생적 취득을 보고했습니다. 이 주식은 MetLife의 비경영진 이사 보상으로 발행되었으며 가격은 $0로 기록되었습니다(주식으로 지급된 보수). 거래 이후 보고자는 33,351주를 실질적으로 소유하게 되었습니다. Form 4 제출은 2025년 10월 3일에 대리인이 서명했습니다. 공시는 이 주식이 회사 주식으로 지급된 이사 보상의 일부를 나타낸다고 명시합니다.
Denise M. Morrison, identifiée comme directrice de MetLife, Inc. (MET), a déclaré une acquisition non dérivée de 534 actions ordinaires MetLife le 01/10/2025. Les actions ont été émises dans le cadre de la compensation des administrateurs non dirigeants et enregistrées à un prix de $0 (la rémunération sous forme d'actions). Suite à la transaction, la personne déclarante détenait de manière bénéficiaire 33 351 actions. Le dépôt du Formulaire 4 a été signé le 03/10/2025 par un mandataire. La disclosure indique que ces actions représentent une partie de la rémunération du directeur payée en actions de l'entreprise.
Denise M. Morrison, als Aufsichtsratmitglied von MetLife, Inc. (MET) identifiziert, meldete einen non-derivativen Erwerb von 534 MetLife Stammaktien am 01.10.2025. Die Aktien wurden im Rahmen der Vergütung für Nichtgeschäftsführer des Vorstands ausgegeben und mit einem Preis von $0 vermerkt (Vorschuss in Aktien bezahlt). Nach der Transaktion besaß die meldende Person letztlich 33.351 Aktien. Die Form 4-Einreichung wurde am 03.10.2025 von einem Bevollmächtigten unterzeichnet. Die Offenlegung besagt, dass diese Aktien einen Teil des in Aktien gezahlten Direktorengehalts darstellen.
Denise M. Morrison، المعروفة ك مديرة في MetLife, Inc. (MET)، أبلغت عن اكتساب غير مشتق لـ 534 سهماً من MetLife العادية في 01/10/2025. تم إصدار الأسهم كجزء من تعويض مديري MetLife غير التنفيذيين وجرِد سعرها بـ $0 (تم الدفع بالأسهم كتعويض). عقب الصفقة، امتلكت الشخص المعلنة بشكل مستفاد 33,351 سهماً. تم توقيع نموذج Form 4 في 03/10/2025 من قبل وكيل. يذكر الكشف أن هذه الأسهم تمثل جزءاً من رواتب المدير المدفوعة بأسهم الشركة.
Denise M. Morrison，被认定为 MetLife, Inc. (MET) 的 董事，在 2025/10/01 报告了对 MetLife 普通股的非衍生取得，共 534 股。该等股票作为 MetLife 的非管理层董事报酬发行，记录的价格为 $0（以股票支付的酬金）。交易完成后，该报备人实际拥有 33,351 股。Form 4 的送交于 2025/10/03 由一位代理签署。披露指出这些股票代表着以公司股票支付的董事报酬的一部分。
- 534 shares acquired as director compensation on 10/01/2025
- Beneficial ownership increased to 33,351 shares
- Grant tied explicitly to non-management director retainer, indicating alignment with shareholders
- None.
Insights
Director received equity compensation aligning interests with shareholders.
This Form 4 discloses a routine equity grant: 534 shares issued as part of non-management director retainer fees. Such grants are standard practice to align non-employee directors with shareholder outcomes and to conserve cash compensation.
The filing explicitly ties the issuance to the non-management director compensation arrangement, showing governance-level alignment rather than an open-market purchase or sale.
Transaction is a non-market issuance; ownership after the grant is 33,351 shares.
The reported transaction code and a $0 price indicate these shares were granted, not purchased. The Form 4 shows the reporting person's total beneficial ownership as 33,351 shares after the grant, a concrete ownership figure useful for monitoring insider holdings.
Denise M. Morrison, identificata come direttrice di MetLife, Inc. (MET), ha riportato un'acquisizione non derivativa di 534 azioni ordinarie MetLife in data 10/01/2025. Le azioni sono state emesse come parte della retribuzione dei membri non esecutivi del consiglio e registrate con un prezzo di $0 (il retainer è stato pagato in azioni). In seguito alla transazione la persona che riporta possedeva in modo utile 33.351 azioni. Il filing Form 4 è stato firmato il 10/03/2025 da un procuratore. La disclosure afferma che queste azioni rappresentano una parte del retainer del direttore pagato in azioni della società.
Denise M. Morrison, identificada como directora de MetLife, Inc. (MET), reportó una adquisición no derivativa de 534 acciones comunes de MetLife el 10/01/2025. Las acciones fueron emitidas como parte de la compensación para directores no ejecutivos y registradas a un precio de $0 (retención pagada en acciones). Tras la transacción, la persona reportante posee beneficiosamente 33.351 acciones. La presentación del Formulario 4 fue firmada el 10/03/2025 por un agente autorizado. La divulgación indica que estas acciones representan una parte de la retención del director pagada en acciones de la empresa.
Denise M. Morrison은 MetLife, Inc. (MET)의 이사로 식별되며, 2025년 10월 1일에 MetLife 보통주 534주의 비파생적 취득을 보고했습니다. 이 주식은 MetLife의 비경영진 이사 보상으로 발행되었으며 가격은 $0로 기록되었습니다(주식으로 지급된 보수). 거래 이후 보고자는 33,351주를 실질적으로 소유하게 되었습니다. Form 4 제출은 2025년 10월 3일에 대리인이 서명했습니다. 공시는 이 주식이 회사 주식으로 지급된 이사 보상의 일부를 나타낸다고 명시합니다.
Denise M. Morrison, identifiée comme directrice de MetLife, Inc. (MET), a déclaré une acquisition non dérivée de 534 actions ordinaires MetLife le 01/10/2025. Les actions ont été émises dans le cadre de la compensation des administrateurs non dirigeants et enregistrées à un prix de $0 (la rémunération sous forme d'actions). Suite à la transaction, la personne déclarante détenait de manière bénéficiaire 33 351 actions. Le dépôt du Formulaire 4 a été signé le 03/10/2025 par un mandataire. La disclosure indique que ces actions représentent une partie de la rémunération du directeur payée en actions de l'entreprise.
Denise M. Morrison, als Aufsichtsratmitglied von MetLife, Inc. (MET) identifiziert, meldete einen non-derivativen Erwerb von 534 MetLife Stammaktien am 01.10.2025. Die Aktien wurden im Rahmen der Vergütung für Nichtgeschäftsführer des Vorstands ausgegeben und mit einem Preis von $0 vermerkt (Vorschuss in Aktien bezahlt). Nach der Transaktion besaß die meldende Person letztlich 33.351 Aktien. Die Form 4-Einreichung wurde am 03.10.2025 von einem Bevollmächtigten unterzeichnet. Die Offenlegung besagt, dass diese Aktien einen Teil des in Aktien gezahlten Direktorengehalts darstellen.
FAQ
What did Denise M. Morrison report on Form 4 for MET?
When was the MET transaction executed and filed?
Was the acquisition a market purchase or a grant?
What was the reason given for the stock issuance?
How many shares does the reporting person own after the transaction?
